What is Biotrial?
Founded in 1989, Biotrial operates as a comprehensive service provider for the pharmaceutical and biotechnology industries, specializing in early-stage development. The company offers an integrated suite of solutions ranging from in vivo pharmacology to complex Phase I and patient-based clinical trials. By maintaining a robust footprint across key global hubs including Rennes, London, Montreal, and New Jersey, Biotrial delivers critical expertise in study design, bioanalysis, and regulatory affairs. Their specialized core labs, which focus on ECG, imaging, and psychometric testing, position them as a high-value partner for firms navigating the rigorous demands of drug development and proof-of-concept validation.
How much funding has Biotrial raised?
Biotrial has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Biotrial
PPP
Public-Private Partnership
What's next for Biotrial?
The recent capital allocation signals a strategic pivot toward enhancing Biotrial's technological and analytical service lines. As the firm moves deeper into its late-stage lifecycle, the focus will likely shift toward expanding its oncology research capabilities and optimizing data management workflows. By leveraging this financing, Biotrial is well-positioned to address the increasing complexity of global regulatory requirements, ensuring that its clients maintain a competitive edge in bringing novel therapeutics to market. Future growth will likely be driven by the integration of advanced imaging and biostatistical tools, further cementing the company's role as a cornerstone of the international clinical development ecosystem.
See full Biotrial company page
